Pulmonary drug delivery
Overcoming the undesirable properties of dry-powder inhalers with novel engineered mannitol particles
Re-engineering the early development process for pulmonary drug-delivery products
Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system?
Nano-sized lipid vectors for the pulmonary co-delivery of anticancer drugs and siRNA in targeted lung cancer treatment
Peptide-coated gold nanoparticles capable of controlling in vitro angiogenesis
Illuminated microbubbles could advance medical applications in targeted drug delivery
Novel topical nanoparticle treatment for Candida wound infection
Industry Update: The latest developments in therapeutic delivery
Interview: Interview with Peter J Barnes
Ask the Experts: The benefits and challenges of pulmonary drug delivery
Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis
Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers
Device factors affecting pulmonary delivery of dry powders
Delivery and performance of surfactant replacement therapies to treat pulmonary disorders
Electrostatics in pharmaceutical aerosols for inhalation
Improved laboratory test methods for orally inhaled products
Mechanisms of absorption and elimination of drugs administered by inhalation
Liposomal formulations for inhalation
Acknowledgements